Weight Loss

WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.

Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.

Ozempic maker Novo Nordisk is disputing Sen. Bernie Sanders' claim that the weight loss drug can be produced for Americans at a fraction of its current price.

Costco members are now getting access to a weight loss program through Sesame. Through the program, they might be able to get highly coveted weight loss medications.

WeightWatchers CEO Sima Sistani sent a memo to employees trying to reassure them as the company's stock continues to suffer following the news that Oprah Winfrey is leaving the board.

Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.

FDA Chief Dr. Robert Califf warned that fake weight loss drugs are emerging in response to shortages of Ozempic and other popular GLP-1 agonists, according to Reuters.

Oprah Winfrey has made the decision to exit the WeightWatchers board, effective in May. Shares for the company have dropped following the announcement.

Novo Nordisk says it Is gradually ramping up supply of its sought-after drug Wegovy. However, the company is still warning patients demand will still outpace supply overall.

Eli Lilly, which makes obesity and diabetes drugs like Zepbound and Mounjaro, has launched a new website that connects patients to telehealth services, but the service worries some health experts.

Lawmakers in Colorado are expected to pass legislation that bans bias based on “fatphobia" to prevent employers and landlords from discriminating against those who are overweight.

Eli Lilly's drug tirzepatide was approved by the Food and Drug Administration to help people who are overweight and have a weight-related medical condition lose weight.

Eli Lilly and Novo Nordisk are seeking to test some of their most popular drugs approved for Type 2 diabetes and weight management in adults on children.

Novo Nordisk, a pharmaceutical company, experienced a decline in its stock prices following a report by financial news agency MarketWire.

Pfizer's oral diabetes drug could join the lineup of sought-after drugs tackling weight loss. A recent study showed promising weight loss results in those with Type 2 diabetes.